Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- May 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Started May 2023; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05876754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876754.